Top Biotech News (9 July 2025)

NIH Ends Animal-Only Study Funding, Mandates New Approach Methodologies

Summary:

The NIH will no longer fund research proposals that rely exclusively on animal testing, instead requiring the integration of organoids, AI models, simulations, and organ-on-chip technologies.

Biopharma Navigates Regulatory Shifts While Advancing Key Therapies

Summary:

Despite policy upheaval under new HHS leadership, the industry achieves significant wins including Lilly’s oral obesity drug readout and rare disease approvals, shaping therapeutic landscapes.

FDA Streamlines CAR-T Cell Therapy Access Through Regulatory Reform

Summary:

Regulators remove burdensome safety requirements for blood cancer treatments, reducing hospital certification needs and expanding community access to life-saving immunotherapies.

Biotech Consolidation Accelerates as Cargo Therapeutics Joins Acquisition Wave

Summary:

CAR-T developer accepts $202 million buyout from Concentra Biosciences following failed lymphoma trial, highlighting industry’s ongoing restructuring amid challenging market conditions.

Trump Administration Targets Pharmaceutical Supply Chains with Massive Tariffs

Summary:

Planned 200% duties on drug imports signal major shift in trade policy, though one-year grace period allows industry time to adapt manufacturing strategies and supply chain operations.

AI Writing Tools Proliferate Across Biomedical Research Publications

Summary:

Analysis reveals one in seven research abstracts likely used artificial intelligence assistance, with distinctive vocabulary patterns emerging since ChatGPT’s widespread adoption in late 2022.

Subscribe to the latest updates in the newsletter

Share your disease area, therapeutic candidate and research objectives.

Related Solutions

Organoid Service
Research Service
Technical Service

ODISEI CNS - Human brain & retinal organoid
solutions for translational CNS discovery.

Please provide the information below, and our team will contact you shortly with brochure and relevant case studies.

Thank you for your submission.

Our team has received your request and will get back to you shortly.
If you do not receive our confirmation email, kindly check your spam or junk folder.